Quick Answer
Context Therapeutics Inc. reported Stockholders Equity of $60.47 million for the year ending 2025.
- Context Therapeutics Inc. showed a decrease of -36.5% in Stockholders Equity from 2024 to 2025.
- This data is from Context Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$22.99 million | Q2 2020: -$15.39 million | Q3 2020: -$16.22 million | Q1 2021: -$17.48 million | Q2 2021: -$22.30 million | Q3 2021: -$23.21 million | Q1 2022: $45.39 million | Q2 2022: $41.65 million | Q3 2022: $38.07 million | Q1 2023: $28.73 million | Q2 2023: $24.00 million | Q3 2023: $18.38 million | Q1 2024: $8.44 million | Q2 2024: $101.10 million | Q3 2024: $83.86 million | Q1 2025: $90.98 million | Q2 2025: $82.54 million | Q3 2025: $73.17 million.
- Over the full 7 years of available data (2019 to 2025), Context Therapeutics Inc.'s Stockholders Equity has grown by 352.4%.
- Historical annual values: Fiscal year 2025: $60.47 million | Fiscal year 2024: $95.27 million | Fiscal year 2023: $11.87 million | Fiscal year 2022: $34.76 million | Fiscal year 2021: $48.27 million | Fiscal year 2020: -$16.92 million | Fiscal year 2019: -$23.96 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: